Prevalence, clinico-pathological features and outcomes of ‘double-hit’ high-grade B-cell non-Hodgkins lymphoma (NHL): a single institution experience

Date

08 Oct 2016

Session

Poster Display

Presenters

Deaglan McHugh

Citation

Annals of Oncology (2016) 27 (6): 313-327. 10.1093/annonc/mdw375

Authors

D.J. McHugh1, P. Gou2, J. Quinn3, P. Thornton4, B. Bird5, S. Sukor6, A. Fortune7, K. Perera8, L. Bacon9, E. Vandenberghe9, R. Flavin10, C. Grant6

Author affiliations

  • 1 Medical Oncology, St James's Hospital, Dublin 8 - Dublin/IE
  • 2 Histopathology, St Vincents University Hospital, Dublin/IE
  • 3 Haematology, Beaumont Hospital, Dublin/IE
  • 4 Haematology, Connolly Hospital Blanchardstown, Dublin/IE
  • 5 Medical Oncology, Bon Secours Hospital, Cork/IE
  • 6 Medical Oncology, St James's Hospital, Dublin/IE
  • 7 Haematology, Mater Misericordiae University Hospital University College Dublin, Dublin/IE
  • 8 Haematology, Midlands Regional Hospital Tullamore, Tullamore/IE
  • 9 Haematology, St James's Hospital, Dublin/IE
  • 10 Histopathology, St James's Hospital, Dublin/IE
More

Resources

Background

MYC/BCL2 (or MYC/BCL6) double hit lymphoma (DHL) is defined as a large B-cell lymphoma with concurrent translocations. Several studies indicate that up to 10% of diffuse large B-cell lymphomas (DLBCLs) harbouring a MYC rearrangement will have a poorer prognosis, worse still when present with a BLC2/6 rearrangement. Currently, there is a paucity of guidelines bridging together this data to decide the most effective therapy for DHL patients.

Methods

From August 2013 to October 2015, all patients with high grade B-cell NHL who had tissue samples referred to the central pathology laboratory at St. James Hospital, Dublin were included for analysis. Patient demographics, clinical features, histopathological details, systemic therapy received and patient-related outcomes were recorded from electronic or paper medical records. All cases were reviewed by a consultant haematopathologist.

Results

152 cases of high-grade B-cell NHL were identified since FISH testing for MYC rearrangement commenced in St. James Hospital. 21 patients displayed MYC rearrangement, 9 of whom had a concurrent BCL2 rearrangement. One patient with MYC and BCL2 rearrangements also had a BCL6 rearrangement. These patients all had germinal centre cell of origin (GC COO) by Hans criteria. 4 patients with DHL had prior follicular lymphoma and 5 patients had no prior lymphoma. Patients were treated with varying regimens including standard or dose-intensified chemo-immunotherapy. All patients with DHL achieving a complete response (CR) were consolidated with transplantation (n = 5), both in first line and salvage settings. 2 patients underwent autologous transplantation and 3 underwent allogeneic transplantation. The 1-year survival for all DHL patients was 67%

Conclusions

In our study of all high-grade NHL, the frequency of DHL was 6%. All patients had GC COO by Hans criteria. We suggest considering referral of all patients with DLBCL for MYC-rearrangement testing at the time of initial diagnosis with consideration given to upfront dose-intensified chemotherapy and early haematogenous cell transplantation referral, once DHL status is known.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings